$0.02
(1.64%)
Add to watchlist
Create an alert
Stocks and Shares ISAHCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The Company is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.
Company Information
About this company
Key people
Hing C. Wong
Chief Executive Officer, Founder, Director
Rebecca Byam
Chief Financial Officer
Lee Flowers
Senior Vice President - Business Development
Peter Rhode
Chief Scientific Officer, Vice President - Clinical Operations
Scott T. Garrett
Independent Chairman of the Board
Lisa M. Giles
Independent Director
Rick S. Greene
Independent Director
Click to see more
Key facts
- Shares in issue2.70m
- EPICHCWB
- ISINUS40423R2040
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$3.30m
- Employees36
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.